Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That’s a significant fail for ABBV insofar as there was hope Imbruvica might work in solid cancers
Sorry it does not work that way Instead of a combo pill that you pay XX. or you can buy two separate generic pills for WAY less. I cannot remember the name but it was a satin along with a high blood pressure combination At the time I had BCBS with 0 deductible so I did not care what it cost. When OB care came around the pill cost Aprox $75 per month the two generic were $3 each.
Just noticed that if you Google "AMRN discussion" the first thing that comes up is a pay-per-click ad from the Gibbs ambulance chasers.
The need remains for anything that works in sarcoma (#msg-144921709).
Just went back and looked at your past 12-15 posts. Kind of scratching my head why you are on this chatroom. Seems your only purpose is to refute anything positive posted by BB. True or what is your purpose in spending time and posted on here negatively so much?
Any new indications would require clinical trials on the targeted outcome. For alzheimer's prevention, that would require a long-term study, similar to R-It. But, for things like dry eye syndrome (or acne), the trials could be short and much cheaper. It is going to be years before any other indications like these could get on label, but V could be used off label for these right now.
Can anyone please refer me to a company that got thru phase three,unpartnered,and with anything vaguely remotely close to the market potential of Vascepa?
But again, he was summarizing a fairly picked group of KOLs (i.e. he didn't cherry pick the KOLs to be negative).
I was a VP in a closely held biotech company in Austin, Tx we were about $50M in sales, and were sold to Applied Biosystems for $275M in 2006, and I did not know about the sale until my shares were exercised. We were subsequently sold 2 more times ending up a Thermo Scientific acquisition, Thermo is a multiB yr in sales corp.
Retail investors and many insiders will never know about negotiations or a sale/merger until it happens
. Under the terms of the acquisition deal, Celgene shareholders will be receiving $50 in cash, one Bristol-Myers share and one tradeable Contingent Value Right for each share of Celgene.
Amarin is probably one of the easiest bolt-on acquisition targets ever for BP. Small employee population, little overlap in operations, easy integration and multi-billion dollar drug. No brainer. I just hope shareholders get their fair share.
RA is a very different animal than OA, which is what I believe you have - the former is an autoimmune disease, the last a degenerative condition - not saying V wouldn't help with RA pain, but doubtful it would make it go away - there's no cure for RA and the current drugs to treat it are awful - they were blamed for the death of Glenn Frey of the Eagles.
What makes you so relevant?
The FDA would be wise to have an On-Label indication by then for Vascepa....problem is the FDA is pretty damn stupid
What I am saying is FDA will allow them DTC ads because FDA does not want to go back to court where it will lose.
As you can see, all Amarin has to pay for in terms of recurring cost are trials for new diseases! Then, the more Vascepa produced to treat more diseases, the less expensive it becomes due to economies of scale.
Physicians here who have a vested interest in this could spend some extra time with their patients and Amarin reps giving real world examples that will need to be shared with the managed care people at Amarin.
There is likely nobody at AMRN 100% dedicated to prepping the sNDA either
I'm also a little disturbed that Nissen continues to be the go-to guy to interview about fish oil/EPA. He is literally the most conflicted physician out there on this topic. I loved reading the most recent Kaiser Health News article where he attempts to walk a very narrow line between bashing Vascepa and bashing EPA fish oil supplements while still holding out hope that "his" trial will be successful. Someone in his position with even a modicum of ethics would abstain from commenting.
There are literally dozens of other cardiologists who are equally or better qualified to speak on the topic.
Herper addresses this in the following tweet series:
Media embargoes! This is the most common complaint about my $AMRN stories. So here's is something all biotech investors should know.
— Matthew Herper (@matthewherper) November 21, 2018
Most healthcare journalists are offered what is called a media embargo by The New England Journal of Medicine and major medical meetings. 1/6 https://t.co/epjImTvQhM
SAGE -6% on 3-month PDUFA extension to 3/19/19:
https://finance.yahoo.com/news/sage-therapeutics-receives-notification-pdufa-123000559.html
You had mentioned a foray into NASH stocks ...MDGL , VKTR ? ...what were you interested in ?
The PPS is going nowhere. I think we are in for a long haul.
What is the MoA by which Vascepa is thought to be effective against dry eye?
upgrade to Strong Buy at Raymond James with a $43 (269% upside) price target
Your point not to run a study testing mineral oil on statin absorption is based in fear of losing money on an investment, not based on what’s actually good for patients, health care spending, and the environment, all of which will be significantly impacted by the label expansion. The truth of the matter is what we should all be after.
I am a gambler down to my toes
That said, I highly doubt there will be any meaningful off-label use of Imfinzi in 1L NSCLC across any PD-L1 expression level. The mental leaps a clinician would have to make to justify such a decision are too great in the face of Keytruda's blanket approvals across the market, let alone any logistical leaps with regard to access and reimbursement.
In my very uneducated opinion, I think 1-2 months of around the clock work would be plenty.
Please don't make this political - take person X. (S)he is running for president. How many attacks you think this person will face during the run? Once one is proven false, there will be another one. It will never stop.
No one has been able to answer my question of why are Amarin waiting for 2019 to submit sNDA? They had access to all the data probably since prior to September 24.
So why does it take 4 months to submit the package?
Yes. Just stop responding to the concern trolls.
"My point is that there is no question. It is a falsehood, fabricated by the shorts. "
Exactly! So WTF are we feeding it?
We won, they lost. Now the scripts roll in and there's nothing the MO crowd can do to stop it.
This board needs to figure it out and stop engaging on a non-issue.
Doing a quick trial is a very sensible idea.
Are they really going to buy a pipeline?
That doesn't make any sense to me.
They should get bought by a non-giant Pharma -- Astra-Zeneca really isn't the worst choice and we know they covet this space -- and then we can hold their stock post deal and still see the runup benefit, albeit to a lesser extent.
AZN could do a cash and stock deal for like $30bn.
Of course, what are we going to do with $1bn?
JL, couldn't this trial be done with relative speed?
Why perform the unnecessary just to give them a pulpit.
Kind of funny to imagine that people who don’t know what the hell “high trigs” are would know what the hell is being talked about if the ad yelled “hard MACE reduced 26%. More likely they would associate MACE with something people carried in their purse as a safety precaution
Any advertising people out there? Anyone know how much a good TV ad campaign like this costs?
It's almost noon!
Anyone want to place a bet as to what time the next ambulance-chasing law firm announces an "investigation" into mineral oil? I think it will be around 2 pm.